Am. J. Respir. Crit. Care Med., Volume 162, Number 2, August 2000, 481-485

Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis

ALAN F. BARKER, LESLIE COUCH, STANLEY B. FIEL, MARK H. GOTFRIED, JONATHAN ILOWITE, KEITH C. MEYER, ANNE O'DONNELL, STEVEN A. SAHN, LEWIS J. SMITH, JACK O. STEWART, TAMMY ABUAN, HEATHER TULLY, JILL VAN DALFSEN, CHARLES D. WELLS, and JOANNE QUAN

Pulmonary and Critical Care Division, Oregon Health Sciences University, Portland, Oregon; Pulmonary Division, University of Texas Health Center, Tyler, Texas; Pulmonary and Critical Care Division, MCP Hahnemann University, Philadelphia, Pennsylvania; Pulmonary Associates, Phoenix, Arizona; Pulmonary Division, Winthrop University Hospital, Mineola, New York; Pulmonary Division, University of Wisconsin, Madison, Wisconsin; Pulmonary and Critical Care Division, Georgetown University Medical Center, Washington, DC; Pulmonary and Critical Care Division, Medical University of South Carolina, Charleston, South Carolina; Pulmonary Division, Northwestern University, Chicago, Illinois; Pulmonary Consultants of Orange County, Orange, California; and PathoGenesis Corporation, Seattle, Washington

We conducted a placebo-controlled, double-blind, randomized study to evaluate the microbiological efficacy and safety of inhaled tobramycin for treatment of patients with bronchiectasis and Pseudomonas aeruginosa. Patients were randomly assigned to receive either tobramycin solution for inhalation (TSI) (n = 37) or placebo (n = 37), which was self-administered twice daily for 4 wk and followed by 2-wk off-drug. At Week 4, the TSI group had a mean decrease in P. aeruginosa density of 4.54 log₁₀ colony-forming units (cfu)/g sputum compared with no change in the placebo group (p < 0.01). At Week 6, P. aeruginosa was eradicated in 35% of TSI patients but was detected in all placebo patients. Investigators indicated that 62% of TSI patients showed an improved medical condition compared with 38% of placebo patients (odds ratio = 2.7, 95% confidence interval [CI] 1.1 to 6.9). Tobramycin-resistant P. aeruginosa strains developed in 11% of TSI patients and 3% of placebo patients (p = 0.36). The mean percent change in FEV₁ percent predicted from Week 0 to Week 4 was similar for the TSI and placebo groups (p = 0.41). More TSI-treated patients than placebo patients reported increased cough, dyspnea, wheezing, and noncardiac chest pain, but the symptoms did not limit therapy. Additional study is warranted to further evaluate TSI in bronchiectasis patients.

This article has been cited by other articles:

				L. K. Moores Unusual Lung Infection, Bronchiectasis, and Cystic Fibrosis ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 1 - 20. [Full Text] [PDF]

				A. E. O'Donnell Bronchiectasis Chest, October 1, 2008; 134(4): 815 - 823. [Abstract] [Full Text] [PDF]

				N. H T t. Hacken, P. J Wijkstra, and H. A M Kerstjens Treatment of bronchiectasis in adults BMJ, November 24, 2007; 335(7629): 1089 - 1093. [Full Text] [PDF]

				D. Bilton, N. Henig, B. Morrissey, and M. Gotfried Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis. Chest, November 1, 2006; 130(5): 1503 - 1510. [Abstract] [Full Text] [PDF]

				C. A. Cannella and S. T. Wilkinson Acute renal failure associated with inhaled tobramycin. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1858 - 1861. [Abstract] [Full Text] [PDF]

				M. Aghajanzadeh, A. Sarshad, H. Amani, and A. Alavy Surgical Management of Bilateral Bronchiectases: Results in 29 Patients Asian Cardiovasc Thorac Ann, June 1, 2006; 14(3): 219 - 222. [Abstract] [Full Text] [PDF]

				M. J. Rosen Chronic Cough Due to Bronchiectasis: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 122S - 131S. [Abstract] [Full Text] [PDF]

				P. A. LoBue Inhaled Tobramycin: Not Just for Cystic Fibrosis Anymore? Chest, April 1, 2005; 127(4): 1098 - 1101. [Full Text] [PDF]

				P. Scheinberg, E. Shore, and on behalf of the PC-TNDS-008 Study Group A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis Chest, April 1, 2005; 127(4): 1420 - 1426. [Abstract] [Full Text] [PDF]

				M E. Drobnic, P. Sune, J B. Montoro, A. Ferrer, and R. Orriols Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa Ann. Pharmacother., January 1, 2005; 39(1): 39 - 44. [Abstract] [Full Text] [PDF]

				E.A. Edwards, I. Narang, A. Li, D.M. Hansell, M. Rosenthal, and A. Bush HRCT lung abnormalities are not a surrogate for exercise limitation in bronchiectasis Eur. Respir. J., October 1, 2004; 24(4): 538 - 544. [Abstract] [Full Text] [PDF]

				R. S. Edson, R. H. Brey, T. J. McDonald, C. L. Terrell, J. T. McCarthy, and J. M. Thibert Vestibular Toxicity Due to Inhaled Tobramycin in a Patient With Renal Insufficiency Mayo Clin. Proc., September 1, 2004; 79(9): 1185 - 1191. [Abstract] [PDF]

				S. M. Moskowitz, J. M. Foster, J. Emerson, and J. L. Burns Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis J. Clin. Microbiol., May 1, 2004; 42(5): 1915 - 1922. [Abstract] [Full Text] [PDF]

				J. Mazieres, M. Murris, A. Didier, J. Giron, M. Dahan, J. Berjaud, and P. Leophonte Limited operation for severe multisegmental bilateral bronchiectasis Ann. Thorac. Surg., February 1, 2003; 75(2): 382 - 387. [Abstract] [Full Text] [PDF]

				A. F. Barker Bronchiectasis N. Engl. J. Med., May 2, 2002; 346(18): 1383 - 1393. [Full Text] [PDF]

				M. J. TOBIN Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788. [Full Text] [PDF]